Sector News

Century Therapeutics changes leadership as CEO steps down

April 15, 2023
Life sciences

Century is one of several companies developing “allogeneic” cell therapies, which involve cells from donors and are meant to be more convenient than personalized, “autologous” CAR-T counterparts. The company was launched by Versant Ventures in 2019 with $250 million in funding — a sizable round that included the financial support of Bayer — and added another $211 million in an initial public offering two years later.

But Century has been swept up in the biotech sector’s downturn since then, a pullback that’s hit cell therapy developers particularly hard. The company has also dealt with growing skepticism around allogeneic treatments, which have struggled to match the high bar set by CAR-T therapies and are dealing with increased competition from bispecific antibodies. Century has lost more than 80% of its value since its IPO and, in January, laid off 25% of its staff and restructured its pipeline. Others such as Celularity and Fate Therapeutics have restructured in the last few months as well.

Century began a Phase 1 trial of a prospective lymphoma treatment in February. The study will test the potential of a repeat dosing regimen, one strategy allogeneic cell therapy developers are evaluating to boost the durability. That effort will, for now, be led by Russotti, a former cell therapy executive with Celgene. READ MORE

By Delilah Alvarado


comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach